Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOX1 | Q9Y5S8 | 20/20 | 0.82 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17835483 | 1.00 | NOX1 (0.82) | NOX1 | |
| SCHEMBL17835763 | 1.00 | NOX1 (0.82) | NOX1 | |
| SCHEMBL31317816 | 1.00 | NOX1 (0.82) | NOX1 | |
| SCHEMBL17835524 | 0.92 | NOX1 (0.71) | NOX1 | |
| SCHEMBL17835766 | 0.92 | NOX1 (0.71) | NOX1 | |
| SCHEMBL17835527 | 0.92 | NOX1 (0.71) | NOX1 | |
| SCHEMBL17835695 | 0.90 | NOX1 (1.00) | NOX1 | |
| SCHEMBL17835539 | 0.89 | NOX1 (0.77) | NOX1 | |
| SCHEMBL17835537 | 0.89 | NOX1 (0.77) | NOX1 | |
| SCHEMBL17835848 | 0.89 | NOX1 (0.89) | NOX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260021079-A1 | NOX INHIBITORS FOR USE IN THE TREATMENT OF ALPORT SYNDROME | CALLIDITAS THERAPEUTICS SUISSE SA (CH) | 2026-01-22 | — | — | US | claimed |
| EP-4522162-A1 | NOX INHIBITORS FOR USE IN THE TREATMENT OF ALPORT SYNDROME | Calliditas Therapeutics Suisse SA (CH) | 2025-03-19 | — | — | EP | claimed |
| WO-2023217764-A1 | NOX INHIBITORS FOR USE IN THE TREATMENT OF ALPORT SYNDROME | CALLIDITAS THERAPEUTICS SUISSE SA (CH) | 2023-11-16 | — | — | WO | claimed |
| US-20210177811-A1 | USE OF NOX INHIBITORS FOR TREATMENT OF CANCER | CALLIDITAS THERAPEUTICS SUISSE SA (CH) | 2021-06-17 | — | — | US | claimed |
| EP-3703747-A1 | USE OF NOX INHIBITORS FOR TREATMENT OF CANCER | GenKyoTex Suisse SA (CH) | 2020-09-09 | — | — | EP | claimed |
| CN-111344013-A | Use of NOX inhibitors for the treatment of cancer | 吉恩基奥泰克斯瑞士股份有限公司 | 2020-06-26 | — | — | CN | claimed |
| EP-3479843-A1 | USE OF NOX INHIBITORS FOR TREATMENT OF CANCER | GenKyoTex Suisse SA (CH) | 2019-05-08 | — | — | EP | claimed |
| US-20190046515-A1 | AMIDO THIADIAZOLE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYOTEX SA (CH) | 2019-02-14 | — | — | US | claimed |
| US-10130619-B2 | Amido thiadiazole derivatives as NADPH oxidase inhibitors | GENKYOTEX SUISSE SA (CH) | 2018-11-20 | — | — | US | claimed |
| US-20170348296-A1 | AMIDO THIADIAZOLE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYOTEX SUISSE SA (CH) | 2017-12-07 | — | — | US | claimed |
| EP-3233847-A1 | AMIDO THIADIAZOLE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GenKyoTex Suisse SA (CH) | 2017-10-25 | — | — | EP | claimed |
| WO-2016098005-A1 | AMIDO THIADIAZOLE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYOTEX SA (CH) | 2016-06-23 | — | — | WO | claimed |
| EP-3034500-A1 | Amido thiazole derivatives as NADPH oxidase inhibitors | GENKYOTEX SA (CH) | 2016-06-22 | — | — | EP | claimed |
| US-20260021079-A1 | NOX INHIBITORS FOR USE IN THE TREATMENT OF ALPORT SYNDROME | CALLIDITAS THERAPEUTICS SUISSE SA (CH) | 2026-01-22 | — | — | US | disclosed |
| EP-4522162-A1 | NOX INHIBITORS FOR USE IN THE TREATMENT OF ALPORT SYNDROME | Calliditas Therapeutics Suisse SA (CH) | 2025-03-19 | — | — | EP | disclosed |
| US-20240358687-A1 | USE OF NOX INHIBITORS FOR TREATMENT OF CANCER | CALLIDITAS THERAPEUTICS SUISSE SA (CH) | 2024-10-31 | — | — | US | disclosed |
| US-20170348296-A1 | AMIDO THIADIAZOLE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYOTEX SUISSE SA (CH) | 2017-12-07 | — | — | US | disclosed |
| EP-3233847-A1 | AMIDO THIADIAZOLE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GenKyoTex Suisse SA (CH) | 2017-10-25 | — | — | EP | disclosed |
| WO-2016098005-A1 | AMIDO THIADIAZOLE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYOTEX SA (CH) | 2016-06-23 | — | — | WO | disclosed |
| EP-3034500-A1 | Amido thiazole derivatives as NADPH oxidase inhibitors | GENKYOTEX SA (CH) | 2016-06-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170348296-A1 | AMIDO THIADIAZOLE DERIVATIVES AS NADPH OXIDASE INHIBITORS | NOX1, NOX5, CYBB | NOX1 1/4885 |
| US-20260021079-A1 | NOX INHIBITORS FOR USE IN THE TREATMENT OF ALPORT SYNDROME | NOX1, NOX5, NOX4 | NOX1 1/4885 |
| US-20190046515-A1 | AMIDO THIADIAZOLE DERIVATIVES AS NADPH OXIDASE INHIBITORS | NOX1, NOX5, CYBB | NOX1 1/4885 |
| US-20240358687-A1 | USE OF NOX INHIBITORS FOR TREATMENT OF CANCER | NOX1, NOX5, NOX3 | NOX1 1/4885 |
| US-10130619-B2 | Amido thiadiazole derivatives as NADPH oxidase inhibitors | NOX1, NOX5, CYBB | NOX1 1/4885 |
| US-20210177811-A1 | USE OF NOX INHIBITORS FOR TREATMENT OF CANCER | NOX1, NOX5, NOX3 | NOX1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.